Who
Alexander Julian Nichols
Chief Strategy & Ops. Ofc
Company insider
Files Form 4 as: Chief Strategy & Ops. Ofc, enGene Therapeutics.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 18 Feb 2023
- Last trade
- 30 Jan 2026
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jan 2026filed 3 Feb 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —195,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —195,000 at $0.00 | filing |
| 29 Jan 2025filed 31 Jan 2025 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 7 Jul 2023filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —101,924 | filing |
| 18 Feb 2023filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —177,935 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.